Hipotiroideo

Alpha-Lipoic Acid is a versatile antioxidant that functions in both aqueous and lipid environments within the lens and retina, recycling vitamins C and E. It has demonstrated protective effects against lens oxidation and cataractogenesis in animal models, and is identified as a key anti-glycation and antioxidant compound for cataract prevention in ocular health literature.

Astaxanthin is a marine xanthophyll carotenoid that crosses the blood-retinal barrier and protects ocular tissues via potent antioxidant and anti-inflammatory activity. Multiple human RCTs at doses of 4–12 mg/day show improvements in visual fatigue, accommodative function, and retinal parameters in aging adults. Research also suggests protection of lens crystallin proteins from oxidative damage relevant to cataract.

Beta-carotene, a provitamin A carotenoid with antioxidant properties, was part of the original AREDS1 formulation (15 mg/day) proven to reduce AMD progression risk by ~25% in an NIH randomized trial. It has also been associated with reduced cataract risk in observational studies. It was replaced by lutein/zeaxanthin in AREDS2 due to lung cancer risk in smokers.

Bilberry (Vaccinium myrtillus) is rich in anthocyanosides that protect retinal capillaries and ocular tissues from oxidative stress relevant to age-related vision decline. Small clinical studies report improvements in visual acuity and contrast sensitivity in AMD patients, and prevention of lens and retinal impairments. Traditional use in European herbal medicine for eye conditions dates back centuries.

Oxidative stress is a significant contributor to age-related cataract, and dietary antioxidants including beta-carotene have been studied for lens protection. The AREDS trial enrolled participants in both AMD and cataract arms, with the antioxidant formula including beta-carotene. Beta-carotene's antioxidant activity in lipophilic lens tissue may slow cataractogenic oxidation.

Crocetin is one of the principal bioactive carotenoid compounds of saffron (Crocus sativus) with demonstrated clinical evidence for improving visual function and retinal health in age-related macular degeneration. Clinical studies using 5–15 mg/day for 3–12 months showed significant improvements in visual acuity, contrast sensitivity, and retinal function measured by electroretinography. Mechanisms include antioxidant, neuroprotective, and anti-angiogenic effects in retinal tissue.

Crocin is the primary active glycoside of saffron (Crocus sativus) and is the precursor metabolized to crocetin in the body. Multiple clinical trials demonstrate that supplementation with saffron extract (containing crocin as the key active) at 20–50 mg/day significantly improved retinal function, visual acuity, and contrast sensitivity in AMD patients. It acts via antioxidant, anti-inflammatory, neuroprotective, and anti-angiogenic mechanisms in ocular tissues.

DHA constitutes over 50% of the fatty acids in retinal photoreceptor cell outer segments, making it structurally critical for retinal function. It was evaluated in the AREDS2 trial (350 mg/day with 650 mg EPA) for AMD protection, and observational AREDS data found high omega-3 intake associated with 30% lower risk of geographic atrophy and neovascular AMD. It has established anti-inflammatory roles in retinal aging.

EPA is an omega-3 fatty acid with anti-inflammatory properties relevant to age-related macular degeneration pathogenesis. It was studied in the AREDS2 trial (650 mg/day combined with DHA) and observational data from the AREDS cohort found high dietary omega-3 (EPA+DHA) intake associated with a 30% lower risk of developing geographic atrophy and neovascular AMD. EPA reduces inflammatory eicosanoid production in the retina.

Ginkgo biloba extract (GBE) has been used in traditional Chinese medicine for vision and is recognized in ocular health for its antioxidant, anti-inflammatory, and vasodilatory properties that improve microcirculation in retinal capillaries. A randomized placebo-controlled trial of normal tension glaucoma patients showed improvement in pre-existing visual field damage with GBE. Scientific reviews confirm GBE's role in several degenerative eye diseases including AMD, though evidence is described as promising but not yet conclusive.

L-carnosine is present in the lens and exerts antioxidant and antiglycation effects that protect against oxidative cataract formation. Its prodrug N-acetylcarnosine (NAC), applied as eye drops, penetrates the cornea and is metabolized to L-carnosine in the anterior chamber. Multiple clinical studies report improvements in lens opacity and visual function with NAC eye drops, though evidence quality is mixed.

Lutein is one of only two carotenoids found in the human lens and retina, where it absorbs blue light and acts as an antioxidant. Epidemiological studies link higher blood lutein levels to up to 27% lower risk of nuclear cataracts. The landmark AREDS2 randomized controlled trial (4,203 participants) demonstrated that lutein/zeaxanthin supplementation slows progression of age-related macular degeneration (AMD).

Lycopene is a potent carotenoid antioxidant found in the ocular tissues (lens and retina) and associated with protection against oxidative damage in age-related eye diseases. Epidemiological studies have linked higher serum lycopene levels to reduced risk of nuclear cataracts and AMD, and the NIH AREDS dietary analysis identified lycopene intake as relevant to ocular health outcomes.

N-Acetyl Carnosine (NAC) applied as eye drops penetrates the cornea and is metabolized to L-carnosine in the lens, where it acts as an antioxidant and anti-glycation agent against age-related cataract. A clinical study of 96 adults with senile cataracts using NAC eye drops found vision improvement in all subjects with primary senile cataract. A 2019 Cochrane review assessed the evidence base but found current trial quality insufficient to draw definitive conclusions.

Omega-3 fatty acids (primarily EPA and DHA) have established roles in retinal structure and anti-inflammatory regulation important for age-related macular health. Observational data from AREDS found high dietary omega-3 intake associated with a 30% lower AMD risk. The AREDS2 trial directly evaluated omega-3 supplementation for AMD; NIH identifies omega-3 fatty acids among the key nutrients for aging eye health.

Quercetin is a flavonoid antioxidant identified as relevant to aging eye health for its ability to inhibit glycation, reduce oxidative stress in lens epithelial cells, and protect retinal cells from oxidative damage. It is cited in ocular health literature as an anti-glycation and antioxidant agent for cataract prevention, and its anti-angiogenic and neuroprotective properties are relevant to AMD.

Resveratrol, a polyphenol found in grape and other plants, has demonstrated protective effects against age-related ocular diseases through antioxidant inhibition of reactive oxygen species in human lens epithelial cells and retinal cells. A rodent study demonstrated that oral resveratrol improved lens elasticity—directly relevant to presbyopia—and retinal antioxidant capacity. It is identified by ocular health authorities as a natural intervention supporting aging eye health.

Saffron (Crocus sativus) and its active compounds crocin and crocetin have been studied in multiple human clinical trials showing significant improvements in visual acuity, contrast sensitivity, and retinal function in AMD patients. Multiple RCTs using 20–50 mg/day saffron or 5–15 mg/day crocin for 3–12 months demonstrated measurable benefits in both dry and wet AMD. Evidence supports anti-angiogenic, neuroprotective, and antioxidant mechanisms.

Triphala demonstrates significant anti-cataract activity in animal models through antioxidant protection of lens proteins. In a selenite-induced rat cataract model, the lowest dose (25 mg/kg) reduced nuclear cataract incidence from 100% to 20%. Lens glutathione, SOD, catalase, and GPx were significantly restored. Human lens trials are lacking.

Vitamin A (retinol) is essential for the synthesis of rhodopsin, the photoreceptor pigment required for low-light vision, and for maintaining the integrity of the cornea and retinal epithelium. Deficiency causes night blindness and increases risk of age-related retinal damage. The AREDS dietary analysis identified vitamin A intake as protective for AMD risk, and it is included in the standard AREDS ocular formulation context.

Vitamin C is a major water-soluble antioxidant concentrated in the lens and vitreous humor of the eye, protecting against UV-induced oxidative damage. It was a core component of the AREDS formulation (500 mg/day) that reduced AMD progression risk by ~25% in the landmark NIH randomized trial. Vitamin C also absorbs UV radiation and supports glutathione synthesis in the lens, protecting against cataract formation.

Vitamin E is a lipid-soluble antioxidant present in retinal membranes that protects polyunsaturated fatty acids from oxidative damage. It was part of the NIH AREDS formulation (400 IU/day) proven to reduce AMD progression risk by ~25%. Epidemiological studies link higher vitamin E intake to reduced cataract risk.

Zeaxanthin, alongside lutein, is one of only two carotenoids concentrated in the human lens and retinal macula. A meta-analysis found that high zeaxanthin blood levels are associated with a 37% lower risk of nuclear cataracts. Zeaxanthin is a core component of the evidence-backed AREDS2 formula for AMD management.

Zinc is the most abundant trace mineral in the eye, found at highest concentrations in the retinal pigment epithelium and choroid. It is a critical cofactor for antioxidant enzymes and plays a role in vitamin A metabolism in the retina. The AREDS1 trial demonstrated that high-dose zinc (80 mg/day) combined with antioxidants reduced AMD progression risk by ~25%.

Eyebright (Euphrasia officinalis) has been used in traditional European herbal medicine for centuries as a remedy for eye ailments including inflammation, redness, and eye strain. It has been incorporated into traditional eye washes and teas for visual conditions. Scientific evidence for specific age-related ocular diseases (cataract, AMD, glaucoma) is currently absent in rigorous clinical trials.

TCM records document the use of Shi Jue Ming for cataracts and age-related visual deterioration. Classical compound formulas containing calcined abalone shell were prescribed for mature cataracts and other degenerative eye conditions.